Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVI ND HB1
- Development stage
- Unknown
- Lead developer
- Navana Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Inhalation, Intranasal, Ophthalmic, Oral
01
Overview
AVI ND HB1 is a live freeze-dried veterinary vaccine containing the Hitchner B1 strain of Newcastle Disease Virus (NDV). Developed by Laprovet and marketed/distributed by Navana Pharmaceuticals, it is indicated for the active immunization of poultry (chickens) against Newcastle Disease. The vaccine is typically administered via eye-drop (intraocular) for primary vaccination or through drinking water (oral) for booster vaccinations.
- Brand names
- AVI ND HB1
- Other names
- Newcastle disease virus vaccine (Hitchner B1 strain)Newcastle disease virus vaccine, Hitchner B1 strain
Beyond the preview
Go deeper on AVI ND HB1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVI ND HB1.